Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Global Market for DNA Vaccines to Reach $2.7 Billion August 25, 2014
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...Global Market for DNA Vaccines to Reach $2.7 Billion August 21, 2014
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...Immune Response BioPharma to Develop In-House Sales Force for Blockbuster Vaccine August 12, 2014
New Jersey-based Immune Response BioPharma, Inc. recently announced its plans to create an in-house sales force for Remune, its HIV...Inovio’s Delivery Technology Powers Durable, Best-in-Class T-Cell Responses From HIV Vaccine July 18, 2013
Inovio Pharmaceuticals, Inc. recently announced the peer-reviewed publication of results from two Phase I trials (HVTN 070 and HVTN 080)...Prokarium Acquires Key Oral Vaccine Technology July 12, 2012
Prokarium Ltd recently announced it completed a key technology acquisition from Emergent BioSolutions Inc. The technology includes Emergent's live Salmonella-based...Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Adjuvant March 29, 2012
Vical Incorporated recently announced researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin-formulated DNA vaccine candidate...Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer April 23, 2024
Nykode Therapeutics ASA recently announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s...Ocugen Announces FDA Clearance of IND Amendment to Initiate Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 With a Broad Retinitis Pigmentosa Indication April 8, 2024
Ocugen, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) amendment to initiate a Phase...Exothera Pledges to Fast-Track RNA Therapies With Expansion of World-First Continuous-Batch RNA Manufacturing Solution Into North America March 26, 2024
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical development time, while enhancing quality and yield….
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits From Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer March 21, 2024
Nykode Therapeutics ASA recently announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates...ENGINEERING BIOLOGY - Scaling Engineering Biology to Accelerate Advances in Healthcare February 28, 2024
Raquel Sanches-Kuiper and Matthew Hayes, PhD, say the development of a benchtop synthesis platform has the potential to expedite the discovery and development time for drugs and biotherapeutics, greatly accelerating the rate at which engineering biology can shape the future of healthcare.
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer February 27, 2024
IMUNON, Inc. recently announced Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a...Merck Animal Health to Acquire Elanco’s Aqua Business February 5, 2024
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries….
FORMULATION FORUM - Lipid Nanoparticles – Carriers for Nucleic Acids Delivery January 26, 2024
Shaukat Ali, PhD, and Jim Huang, PhD, describe the role of individual components in aggregation, packing, stability, efficacy, and potency of nucleic acids, the understanding of which is important to achieve better designed and smarter formulations, and robust scale up and manufacturing of LNPs.
GDMC Secures $21-Million Growth Capital Funding to Expand Global Genetic Medicines Design & Manufacturing Operations January 25, 2024
Genetic Design and Manufacturing Corporation (GDMC) recently announced a Series A funding of $21 million. The funding round is led...Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND January 16, 2024
Abzena has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. The platforms will….
Ardena's New Aseptic Fill-Finish Plant in Ghent Receives GMP License November 29, 2023
Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has been granted a Good Manufacturing Practice (GMP) license by the….
IMUNON Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer October 18, 2023
IMUNON, Inc. recently announced the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab in...FORMULATION FORUM - CUBOSOMES – The Next Generation of Lipid Nanoparticles for Drug Delivery October 2, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, shed light on the design and formation of cubosomes with special focus on their applications for delivery of hydrophobic and hydrophilic small and large molecules, including oncology drugs and polynucleotides (DNA, mRNA, and siRNA).
KBI Biopharma Expands Global Portfolio With Launch of SUREmAb for Faster Monoclonal Antibody Development & Manufacturing September 12, 2023
KBI Biopharma, Inc., a JSR Life Sciences company, recently announced the launch of SUREmAb, an offering built on the robustness...
